A walk through the mTOR-ketamine story: Li et al. 2010's rat rapamycin result, then the complications: Autry's BDNF/tonic-brake pathway, the (R)/(S)-ketamine enantiomer split, and the human trial where rapamycin didn't block ketamine's effect and improved outcomes instead. We land on mTOR as a real but conditional node, not a universal gatekeeper.

Three competing models of where psychedelic plasticity actually comes from, and why they may not be describing the same thing.

DMT builds inner worlds; 5-MeO-DMT dissolves them. This piece examines what neural and pharmacological mechanisms might explain that divergence, from default mode network dynamics and hippocampal theta oscillations to the opposing effects of 5-HT2A and 5-HT1A receptor activity on the circuits that generate internally sourced visual space.

The entropic brain hypothesis, first proposed in 2014, has just received its most comprehensive update. This piece walks through what twelve years of evidence has established, what a concurrent psilocybin biomarker study means for drug development, and where the model's open questions sit.

Addiction is rarely only one broken circuit. Psychedelics help us understand that: ibogaine and psilocybin work through different mechanisms (plasticity, neurotrophic repair, and withdrawal interruption), showing why a durable treatment likely needs to hit more than one.

Most accounts of depression focus on mood. This piece focuses on something more specific: the loss of the future self as a neurobiological event, and what it might take to get it back. From Perrault's frozen court to a collapsed third set at Roland Garros to the demoralization of a terminal diagnosis, The Arrested Self traces a single mechanism across three very different timescales, before arriving at what psilocybin actually does, and why it might not be the same thing as an antidepressant.

Fewer than half of MDD patients respond to their first antidepressant. Three decades of biomarker research have not solved that, partly because antidepressants work too slowly to catch the biological moment of response. Psilocybin's effects unfold over hours, not weeks, giving researchers a rare window to watch the brain reorganize in real time. This piece asks whether that window could finally yield the biomarker signal the field has been looking for.

Is therapy during integration sessions necessary for an optimized therapeutic effect?

Psilocybin does not access traumatic memories directly. It dismantles the cognitive architecture that holds them in place. We examine how 5-HT2A agonism disrupts the brain's top-down predictive machinery, producing ego dissolution and a neuroplastic window in which rigid fear-based priors can be rebuilt.

MDMA does not force memories to the surface. It lowers the emotional barrier that keeps patients from approaching them. We examine how amygdala suppression and BDNF-driven neuroplasticity create a directed, therapist-guided window for traumatic memory reconsolidation. We also look at methylone, a second entactogen working the same transporter machinery, which achieves durable PTSD symptom reduction without a therapist or an altered state.

Ibogaine's polypharmacology triggers a dream-like life review that can last up to twenty-four hours. We examine how NMDA antagonism, kappa opioid agonism, and a proposed GDNF neurotrophic loop combine to create a prolonged window of dissociated memory access unlike anything else in the psychedelic toolkit.

The β-factor measures which way a 5-HT2A ligand leans between Gq and β-arrestin, but not how hard it pushes. That single limitation unravels most of the mechanistic narrative the neuroplastogen field has built around signaling bias.

Psilocybin may be misframed as an antidepressant, when its core effect is reshaping meaning and beliefs via the 5-HT2A receptor. The article argues its strongest clinical potential lies in treating demoralization rather than depression.

Psychedelic neuroscience is currently shaped by two influential frameworks that appear, at first glance, to contradict each other. Let's take a closer look.

Let’s take a closer look at how psychedelics engage cortical 5-HT2A receptor populations and why their location and function matter. From somatodendritic destabilization of pyramidal neurons to amplified glutamate release and thalamocortical gating breakdown, this cascade offers a mechanistic bridge between receptor binding and large-scale changes in brain network organization.

5-MeO-DMT uniquely engages both 5-HT2A receptor and 5-HT1A receptor, enabling rapid plasticity without strong hallucinations. This balance may explain its intense yet calm effects and its promise as a next-generation therapeutic model.